Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance.

McCoy RG, Irving BA, Soop M, Srinivasan M, Tatpati L, Chow L, Weymiller AJ, Carter RE, Nair KS.

Mayo Clin Proc. 2012 Jun;87(6):561-70. doi: 10.1016/j.mayocp.2012.02.014. Erratum in: Mayo Clin Proc. 2013 Aug;88(8):903-4.

2.

Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians.

Raji A, Gerhard-Herman MD, Williams JS, O'connor ME, Simonson DC.

Diabet Med. 2006 May;23(5):537-43.

PMID:
16681563
3.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947.

PMID:
11874944
4.

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.

PMID:
20015525
5.

Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.

Metabolism. 2009 Aug;58(8):1059-66. doi: 10.1016/j.metabol.2009.03.007. Epub 2009 Jun 18.

PMID:
19394976
6.

Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.

Rudovich NN, Weickert MO, Pivovarova O, Bernigau W, Pfeiffer AF.

Diabetes Technol Ther. 2011 Jun;13(6):615-23. doi: 10.1089/dia.2010.0235. Epub 2011 Apr 13.

PMID:
21488802
7.

Effect of insulin sensitizer therapy on amino acids and their metabolites.

Irving BA, Carter RE, Soop M, Weymiller A, Syed H, Karakelides H, Bhagra S, Short KR, Tatpati L, Barazzoni R, Nair KS.

Metabolism. 2015 Jun;64(6):720-8. doi: 10.1016/j.metabol.2015.01.008. Epub 2015 Jan 22.

8.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
9.

Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.

Maffioli P, Fogari E, D'Angelo A, Perrone T, Derosa G.

Eur J Gastroenterol Hepatol. 2013 Sep;25(9):1113-22. doi: 10.1097/MEG.0b013e3283608317.

PMID:
23524525
10.

Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.

Ciaraldi TP, Aroda V, Mudaliar SR, Henry RR.

Metabolism. 2013 Nov;62(11):1587-96. doi: 10.1016/j.metabol.2013.07.004. Epub 2013 Aug 17.

PMID:
23958241
11.

Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.

Derosa G, Mereu R, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Palumbo I, Maffioli P, Randazzo S, Cicero AF.

J Clin Pharm Ther. 2010 Oct;35(5):565-79. doi: 10.1111/j.1365-2710.2009.01132.x.

PMID:
20831680
12.
13.

Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.

Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P.

Pharmacotherapy. 2013 Aug;33(8):817-26. doi: 10.1002/phar.1301. Epub 2013 Jun 6.

PMID:
23744726
14.

Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.

Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Numao T, Fukuda T, Shimada K, Kario K.

Hypertens Res. 2007 Jan;30(1):23-30.

PMID:
17460368
15.

Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity.

van Tits LJ, Arioglu-Oral E, Sweep CG, Smits P, Stalenhoef AF, Tack CJ.

Neth J Med. 2005 Jul-Aug;63(7):250-5.

16.

Diabetes treatments have differential effects on nontraditional cardiovascular risk factors.

Fonseca VA, Theuma P, Mudaliar S, Leissinger CA, Clejan S, Henry RR.

J Diabetes Complications. 2006 Jan-Feb;20(1):14-20.

PMID:
16389162
18.

Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.

Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, Federici M, Gastaldelli A, Defronzo RA, Folli F.

Diabetologia. 2013 Oct;56(10):2153-63. doi: 10.1007/s00125-013-2976-z. Epub 2013 Jun 30.

PMID:
23811853
19.

Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.

Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P.

Intern Med. 2013;52(19):2179-87. Epub 2012 Mar 1.

20.

Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.

Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF, Maffioli P.

Diabetes Technol Ther. 2012 Jun;14(6):475-84. doi: 10.1089/dia.2011.0278. Epub 2012 Apr 18.

PMID:
22512264

Supplemental Content

Support Center